BioCryst Pharmaceuticals, Inc. BCRX
7.45 USD -0.16 (-2.10%)
Regular-session close
7.45 0.00 0.00%
After hours · Nov 16, 4:34 PM ET
7.41 Day range 7.74
6.23 52-week range 11.22
- YTD
- -4.49%
- 1 year
- +5.23%
News
benzinga.com BioCryst Pharma Announces New Real-World Evidence On Use Of Once-Daily ORLADEYO For Patients With Hereditary Angioedema, Showing Reductions In Hospitalizations And Emergency Department Visits —Two real-world studies demonstrate reductions in healthcare resource utilization in HAE patients who initiated or switched to ORLADEYO® from another prophylactic therapy—RESEARCH TRIANGLE PARK,…
globenewswire.com BioCryst Presents New Real-World Evidence Showing Reduced Angioedema-Related Medical Visits After Switching to ORLADEYO® (berotralstat) at ACAAI 2026 Annual Scientific Meeting — Two real-world studies demonstrate reductions in healthcare resource utilization in HAE patients who initiated or switched to ORLADEYO ® from another prophylactic therapy —
zacks.com 4 Commercial-Stage Biotechs Poised for Sustained Revenue Growth TGTX, BCRX, INSM and MDGL are expanding product sales through rising demand, broader patient access and new market opportunities.benzinga.com Wedbush Maintains Outperform on BioCryst Pharma, Lowers Price Target to $17 Wedbush analyst Laura Chico maintains BioCryst Pharma (NASDAQ:BCRX) with a Outperform and lowers the price target from $18 to $17.
benzinga.com BioCryst Pharma Q3 2026 Earnings Call Transcript BioCryst Pharma (NASDAQ:BCRX) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.Benzinga APIs provide…benzinga.com BioCryst Pharma Raises FY2026 Sales Guidance from $690.000M-$715.000M to $715.000M-$730.000M vs $710.134M Est BioCryst Pharma (NASDAQ:BCRX) raises FY2026 sales outlook from $690.000 million-$715.000 million to $715.000 million-$730.000 million vs $710.134 million estimate.
benzinga.com Two Pills, One Target: Analyst Bets on Pharvaris as Clinical Risks Fade Bank of America upgrades Pharvaris to Buy with a new price target, citing reduced clinical risk for deucrictibant in hereditary angioedema despite market competition.benzinga.com FDA Approves BioCryst Pharma’s sNDA For Use Of Oral Pellet Formulation Of Once-Daily ORLADEYO For Prophylactic Therapy In Adults And Adolescents Aged 12 Years And Older —Expands BioCryst portfolio of targeted oral prophylactic therapy options to meet patients’ individual needs and preferences— —ORLADEYO is the first and only targeted oral prophylactic therapy with…
